QT Vascular

QT Vascular: UOB Kay Hian reckons QT Vascular has all the right ingredients as a possible takeover target - exceptional topline growth, expanding product acceptance and an innovative product growth strategy. House expects its 120-140% y/y sales growth to sustain through 2014-15 as 4Q14 revenue is expected to benefit from China and Japan shipment orders. We view its flagship product, Chocolate® PTA, as well as regulatory approvals in Asia as potential near-term catalysts. UOB Kay Hian maintains BUY with TP of $0.60.